We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Embecta to Acquire Owen Mumford to Expand Drug-Delivery Portfolio
Read MoreHide Full Article
Key Takeaways
Embecta agreed to acquire Owen Mumford for up to $199.4M to expand into drug delivery platforms.
EMBC targets growth via Aidaptus auto-injector and broader chronic care offerings across therapies.
Embecta expects revenue contribution by 2027, with long-term returns despite near-term dilution.
Embecta Corp. (EMBC - Free Report) recently announced a definitive agreement to acquire Owen Mumford Holdings Limited, a pioneer in developing advanced drug delivery systems and medical device solutions, making a strategic move to expand beyond its core diabetes franchise and shift toward high-value drug delivery platforms and global growth.
The transaction, valued at up to $199.4 million (£150 million), includes an upfront payment of $133 million (£100 million) and an additional $66.4 million (£50 million) tied to the sales performance of Owen Mumford’s Aidaptus auto-injector platform. Expected to close in third-quarter fiscal 2026, the deal is approved by EMBC’s board and awaits regulatory clearance.
Management expressed strong enthusiasm about the acquisition of Owen Mumford, recognizing its strong track record in innovation, product quality and patient-centered design. The acquisition is expected to drive sustainable revenue growth while advancing Embecta’s transition into a broad-based medical supplies company. This shift will enable the company to offer drug delivery platforms to pharmaceutical partners and better serve patients across multiple chronic care areas, including obesity, diabetes, autoimmune diseases and anaphylaxis.
Likely Trend of EMBC Stock Following the News
Shares of EMBC have lost 2.5% since the announcement on Thursday. Over the past six months, shares of the company have dropped 39.1% compared with the industry’s 3.2% decline and the S&P 500’s 1% fall.
In the long run, the acquisition of Owen Mumford is expected to strengthen Embecta’s growth by adding a differentiated drug-delivery platform, including Aidaptus, and expanding its chronic care portfolio. By leveraging Embecta’s global presence in more than 100 countries, the deal creates opportunities to scale Owen Mumford’s products internationally. It also enhances manufacturing efficiencies through combined expertise. The transaction is projected to support revenue growth and deliver increasing returns over time, reinforcing Embecta’s shift toward a broader, high-growth medical supplies and drug-delivery business.
EMBC currently has a market capitalization of $526.47 million.
Image Source: Zacks Investment Research
More on the Acquisition
The transaction is expected to deliver strategic and financial benefits by introducing a differentiated drug-delivery platform that supports pharmaceutical partners across multiple therapeutic areas, backed by a strong intellectual property portfolio. The standout asset is Aidaptus — Owen Mumford’s auto-injector — which features a patient-centric design and innovative technology. Its single form factor and unified assembly process simplify large-scale manufacturing while reducing production changeovers and supply chain complexity.
The acquisition will broaden EMBC’s chronic care device portfolio and enable the company to leverage its commercial presence in over 100 countries. With 80% of Owen Mumford’s fiscal 2025 revenues generated in the U.K. and the United States, there is significant potential to expand these products globally through Embecta’s established distribution network and commercial infrastructure.
Furthermore, the combination of Owen Mumford’s expertise in device design, molding and assembly with Embecta’s high-volume manufacturing capabilities is expected to drive operational efficiencies and increase production capacity, supporting future growth and product development initiatives.
Embecta expects the deal to contribute to revenue growth starting in fiscal 2027. While it will be initially dilutive to net income, the transaction is projected to deliver high-single-digit returns on invested capital by year four. This aligns with a disciplined capital allocation approach, balancing near-term pressure with long-term value creation.
The decision to finance the deal through its revolving credit facility suggests confidence in cash flow generation while maintaining flexibility to reduce debt over time.
Gavin Jones, managing director of Owen Mumford, said that the company has built a 70-year legacy of delivering innovative solutions with strong long-term growth prospects. By combining its capabilities with Embecta’s portfolio and global commercial reach, the companies are well positioned to accelerate innovation. This partnership is expected to enhance the quality of life for people managing chronic conditions while also unlocking new growth opportunities for customers and employees alike.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the drug delivery devices market is valued at $321.05 billion in fiscal 2026 and is expected to witness a CAGR of 5.8% through fiscal 2035.
Factors like the rising prevalence of chronic diseases, advancements in medical device technology, growth of the biopharmaceutical industry and strategic mergers, acquisitions and investments are boosting the market’s growth.
Other News
Embecta made strong progress on the international brand transition initiative, with major completion expected by the end of fiscal 2026.
The company strengthened the U.S. Medicare segment by securing an additional exclusive Medicare Part D contract and renewing advantaged formulary positioning with the top three Medicare Part D payers.
EMBC completed product design and installed assembly line equipment for market-appropriate pen needles and syringes, currently undergoing manufacturing validation.
It moved over one-third of more than 30 identified B2B generic partnerships into either contract discussions or finalized agreements.
Embecta continued advancing efforts to broaden the availability of right-sized GLP-1 retail packaging tailored for weekly injection therapies.
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Embecta to Acquire Owen Mumford to Expand Drug-Delivery Portfolio
Key Takeaways
Embecta Corp. (EMBC - Free Report) recently announced a definitive agreement to acquire Owen Mumford Holdings Limited, a pioneer in developing advanced drug delivery systems and medical device solutions, making a strategic move to expand beyond its core diabetes franchise and shift toward high-value drug delivery platforms and global growth.
The transaction, valued at up to $199.4 million (£150 million), includes an upfront payment of $133 million (£100 million) and an additional $66.4 million (£50 million) tied to the sales performance of Owen Mumford’s Aidaptus auto-injector platform. Expected to close in third-quarter fiscal 2026, the deal is approved by EMBC’s board and awaits regulatory clearance.
Management expressed strong enthusiasm about the acquisition of Owen Mumford, recognizing its strong track record in innovation, product quality and patient-centered design. The acquisition is expected to drive sustainable revenue growth while advancing Embecta’s transition into a broad-based medical supplies company. This shift will enable the company to offer drug delivery platforms to pharmaceutical partners and better serve patients across multiple chronic care areas, including obesity, diabetes, autoimmune diseases and anaphylaxis.
Likely Trend of EMBC Stock Following the News
Shares of EMBC have lost 2.5% since the announcement on Thursday. Over the past six months, shares of the company have dropped 39.1% compared with the industry’s 3.2% decline and the S&P 500’s 1% fall.
In the long run, the acquisition of Owen Mumford is expected to strengthen Embecta’s growth by adding a differentiated drug-delivery platform, including Aidaptus, and expanding its chronic care portfolio. By leveraging Embecta’s global presence in more than 100 countries, the deal creates opportunities to scale Owen Mumford’s products internationally. It also enhances manufacturing efficiencies through combined expertise. The transaction is projected to support revenue growth and deliver increasing returns over time, reinforcing Embecta’s shift toward a broader, high-growth medical supplies and drug-delivery business.
EMBC currently has a market capitalization of $526.47 million.
Image Source: Zacks Investment Research
More on the Acquisition
The transaction is expected to deliver strategic and financial benefits by introducing a differentiated drug-delivery platform that supports pharmaceutical partners across multiple therapeutic areas, backed by a strong intellectual property portfolio. The standout asset is Aidaptus — Owen Mumford’s auto-injector — which features a patient-centric design and innovative technology. Its single form factor and unified assembly process simplify large-scale manufacturing while reducing production changeovers and supply chain complexity.
The acquisition will broaden EMBC’s chronic care device portfolio and enable the company to leverage its commercial presence in over 100 countries. With 80% of Owen Mumford’s fiscal 2025 revenues generated in the U.K. and the United States, there is significant potential to expand these products globally through Embecta’s established distribution network and commercial infrastructure.
Furthermore, the combination of Owen Mumford’s expertise in device design, molding and assembly with Embecta’s high-volume manufacturing capabilities is expected to drive operational efficiencies and increase production capacity, supporting future growth and product development initiatives.
Embecta expects the deal to contribute to revenue growth starting in fiscal 2027. While it will be initially dilutive to net income, the transaction is projected to deliver high-single-digit returns on invested capital by year four. This aligns with a disciplined capital allocation approach, balancing near-term pressure with long-term value creation.
The decision to finance the deal through its revolving credit facility suggests confidence in cash flow generation while maintaining flexibility to reduce debt over time.
Gavin Jones, managing director of Owen Mumford, said that the company has built a 70-year legacy of delivering innovative solutions with strong long-term growth prospects. By combining its capabilities with Embecta’s portfolio and global commercial reach, the companies are well positioned to accelerate innovation. This partnership is expected to enhance the quality of life for people managing chronic conditions while also unlocking new growth opportunities for customers and employees alike.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the drug delivery devices market is valued at $321.05 billion in fiscal 2026 and is expected to witness a CAGR of 5.8% through fiscal 2035.
Factors like the rising prevalence of chronic diseases, advancements in medical device technology, growth of the biopharmaceutical industry and strategic mergers, acquisitions and investments are boosting the market’s growth.
Other News
Embecta made strong progress on the international brand transition initiative, with major completion expected by the end of fiscal 2026.
The company strengthened the U.S. Medicare segment by securing an additional exclusive Medicare Part D contract and renewing advantaged formulary positioning with the top three Medicare Part D payers.
EMBC completed product design and installed assembly line equipment for market-appropriate pen needles and syringes, currently undergoing manufacturing validation.
It moved over one-third of more than 30 identified B2B generic partnerships into either contract discussions or finalized agreements.
Embecta continued advancing efforts to broaden the availability of right-sized GLP-1 retail packaging tailored for weekly injection therapies.
Embecta Corp. Price
Embecta Corp. price | Embecta Corp. Quote
EMBC’s Zacks Rank & Key Picks
Currently, EMBC has a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, sporting a Zacks Rank #1 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.